Angiocidin Protein Tumor Growth Arrest

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for tumors like glioma, breast cancer, and leukemia are limited in effectively inhibiting tumor growth and metastasis, and existing therapies often have debilitating side effects or limited efficacy in promoting healthy cell differentiation.

Innovation Solution

Administration of angiocidin, either alone or complexed with growth factors such as FGF-2, NGF, BDNF, or EGF, to induce growth arrest, differentiation, and apoptosis in tumor cells, thereby inhibiting tumor proliferation and promoting healthy stem cell differentiation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for tumors are used, then tumor growth inhibition is achieved, but debilitating side effects occur and efficacy in promoting healthy cell differentiation is limited

Engineering Contradiction:

Improvetumor growth inhibition efficacyVSAvoiddebilitating side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the biochemical parameters of tumor treatment by administering angiocidin, a protein that specifically targets tumor cell pathways. This alters the mechanism of action from conventional cytotoxic approaches to a more selective protein-based therapy, achieving tumor growth inhibition while reducing harmful side effects through targeted molecular interaction

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

Angiocidin serves as an intermediary substance that mediates between the treatment administration and tumor cell response. It complexes with growth factors to modulate their activity, creating a controlled intermediate state that promotes differentiation and growth arrest without the extreme cytotoxicity of conventional treatments

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If cytotoxic chemotherapy is used to treat tumors, then tumor cell destruction is achieved, but healthy cell differentiation is inhibited and toxicity increases

Engineering Contradiction:

Improvetumor cell destruction rateVSAvoidtoxicity to healthy cells

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful overexpression of growth factors in tumors into a beneficial therapeutic mechanism. By administering angiocidin that complexes with these growth factors, the treatment harnesses the tumor's own growth factor environment to induce differentiation and growth arrest, turning the tumor's proliferative drive into a mechanism for its own suppression while sparing healthy cells

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

Instead of using cytotoxic agents that kill tumor cells directly, the patent inverts the approach by using angiocidin to promote tumor cell differentiation and growth arrest. This reverses the conventional kill-based paradigm to a differentiation-based strategy, achieving tumor control through biological maturation rather than destruction, thereby reducing toxicity to healthy cells

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS9526758B2Administration of angiocidin for arresting the growth of a tumor cell

Publication Date: 2016.12.27 TEMPLE UNIV

AI summary

Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.